Iceland· IS-EU/1/22/1659/001-004
Xenpozyme
A olipudase alfa product containing olipudaseum inn alfa, registered in Iceland by Genzyme Europe B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Olipudase alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB25 (olipudase alfa), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Olipudase alfa · ATC A16AB25
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Olipudaseum INN alfa
- Manufacturer
- Genzyme Europe B.V.
- Country
- Iceland (IS)
- ATC code
- A16AB25
- ATC class
- Olipudase alfa
- Defined daily dose
- 15 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Olipudase alfa in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXENPOZYMESanofi B.V., Amsterdam
- SwitzerlandXenpozyme 20 mg, poudre pour solution à diluer pour perfusionSanofi-Aventis (Suisse) SA
- FinlandXenpozymeSanofi B.V.
- United KingdomXenpozyme 20mg powder for concentrate for solution for infusion vialsSanofi
- IrelandXenpozyme 20 mg powder for concentrate for solution for infusionSanofi B.V.
- NorwayXenpozymeSanofi B.V.
- PolandXenpozymeSanofi B.V.
- BelgiumXenpozyme 20 mgSanofi
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Xenpozyme
- Norway · Xenpozyme
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/df55c7b8-5691-4374-aa1d-e3e218c29263 GET /v1/drugs/df55c7b8-5691-4374-aa1d-e3e218c29263?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stofn fyrir innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "A16AB25",
"marketed": false,
"strength": "20 mg",
"ma_number": "EU/1/22/1659/001-004",
"substance": "Olipudaseum INN alfa",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "44736"
}See everything about olipudase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.